Dose Reduction of Lopinavir in Children

HIV Infections Clinical Trial

Official title:

Pharmacokinetics and Efficacy of Low- or Standard-dose of Lopinavir/Ritonavir (Kaletra®) in PI-naïve HIV-1 Infected Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00887120
• Other study ID #: HIV-NAT045
• Status: Completed
• Phase: Phase 2
• Start date: April 2007
• Est. completion date: February 2009

Study information

• Verified date: July 2020
• Source: The HIV Netherlands Australia Thailand Research Collaboration
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in ARV PI naive HIV-1 infected Thai children.

To study clinical and immunological efficacy after 48 weeks of lopinavir/ritonavir in PI naïve HIV-1 infected Thai children

Description:

In 2002, the Thai Ministry of Public Health (MOPH) launched the National Access to Antiretroviral Program for People living with HIV/AIDS (NAPHA) with the aim of providing treatment to all Thai patients who needed antiretroviral treatment. By the end of 2005, 80,000 HIV-infected Thais were treated in the NAPHA program, including about 6,000 children. The antiretroviral treatment regimen consists of three antiretroviral drugs (ARV). The first-line regimen used in NAPHA are mainly generic drugs produced by Thai government pharmaceutical organization (GPO), including a fixed-drug combination of stavudine, lamivudine, and nevirapine (GPOvir);and a fixed-drug combination of zidovudine, lamivudine, and nevirapine (GPOvir-Z). Majority of patients respond very well with first-line regimen(1,2), however about 15% of patients have drug resistance to first-line regimen and require second-line regimen(3). The protease inhibitors (PIs) is used as a second-line regimen, however there are limitations in terms of cost and metabolic complications(4).

Lopinavir/ritonavir is the most widely use protease inhibitors in children because of its high efficacy and a syrup formulation that easy to use in small children. There is evidence supported that the recommended dose according to US-FDA or EU guidelines resulting in much higher plasma blood level in Thai children. Data from 19 Thai children demonstrated Cmin of 5.9 mg/L compare to 3.4 mg/L in US children when use the same dose (the minimum acceptable Cmin is 1.0 mg/L) (5,6). There is a study HIVNAT019, which demonstrated acceptable LPV plasma concentration and treatment outcome in Thai HIV-infected adult when use reduced dose of LPV/r 266mg/66 mg compare to standard dose of 400mg/100mg (7).

Therefore, the study of pharmacokinetic of low dose of LPV/r in Thai HIV-infected children is very important to assess the safety and efficacy of this strategy. This will lead to appropriate ARV dose in children to reduce long-term adverse events, and also reduce the ARV cost.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: February 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria:

• Age from 2- 18 years old

• Documented positive test for HIV-1 infection

• PI-naïve

• HIV RNA viral load > 1,000 copies

• Written informed consent

Exclusion Criteria:

• Active opportunistic infection

• Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.

• Use of concomitant medication that may interfere with the pharmacokinetics of lopinavir/ritonavir

• Pregnancy or lactating

• Inability to understand the nature and extent of the study and the procedures required.

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Lopinavir/ritonavir standard dose According to WHO simplified dosing table
BW 6-7.9 kg: 1.5 mL oral q 12 hr BW 8.0-16.9 kg: 2.0 ml oral q 12 hr BW 17.0-19.9 kg: 2.5 ml oral q 12 hr BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr BW 30.0-34.9 kg: 4.0 ml oral q 12 hr BW > 35 kg: 5.0 ml oral q 12 hr Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
• Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
BW 6-7.9 kg: 1.0 mL oral q 12 hr BW 8.0-16.9 kg: 1.5 ml oral q 12 hr BW 17.0-19.9 kg: 1.8 ml oral q 12 hr BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr BW 30.0-34.9 kg: 3.0 ml oral q 12 hr BW > 35 kg: 3.5 ml oral q 12 h Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)

Locations

Country	Name	City	State
Thailand	HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok	Bangkok

Sponsors (2)

Lead Sponsor	Collaborator
The HIV Netherlands Australia Thailand Research Collaboration	Ministry of Education, Thailand

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pharmacokinetics of standard vs low dose LPV/r		4 weeks after start ART
Secondary	efficacy and safety of standard and low dose LPV/r		48 weeks

External Links

•   HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)